SLRX Salarius Pharmaceuticals

Salarius Pharmaceuticals to Present at BIO Investor Forum Digital

Salarius Pharmaceuticals to Present at BIO Investor Forum Digital
EN
13/10/2020

Underlying

SLRXSalarius Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Salarius Pharmaceuticals

 PRESS RELEASE
Free
SLRX Salarius Pharma...

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints ...

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board Decoy’s development of novel peptide-conjugate therapeutics arising from its proprietary IMP3ACT™ platform to benefit from Dr. Langer’s extensive scientific knowledge and experience CAMBRIDGE, Mass. and HOUSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate therapeutics, announces that Massachusetts Institute of Techn...

April 16, 2025 1 EN
 PRESS RELEASE
Free
SLRX Salarius Pharma...

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces...

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses These candidates, previously shown to be active in vitro against respiratory syncytial virus (RSV) and human parainfluenza virus 3 (hPIV3), show the potential for Decoy’s novel platform to address both significant commercial opportunities and emerging viral threats with a single molecule CAMBRIDGE, Mass. and HOUSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics Inc. (Decoy), a privately held preclinical biopharmaceutic...

March 26, 2025 1 EN
 PRESS RELEASE
Free
SLRX Salarius Pharma...

Salarius Pharmaceuticals Reports 2024 Financial Results and Provides B...

Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of novel peptide conjugate therapeutics for treating respiratory viruses and cancer Updates expected later this year from the MD Anderson Cancer Center (MDACC) investigator-initiated Phase 1/2 clinical trial of seclidemstat in combination with azacitidine to treat hematologic cancers HOUSTON, March 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: SLRX), a clinical-stage bi...

March 24, 2025 1 EN
 PRESS RELEASE
Free
SLRX Salarius Pharma...

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Inv...

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers HOUSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: SLRX) announces that patient enrollment will resume in the investigator-initiated Phase 1/2 clinical trial evaluating seclidemstat in combination with azacitidine for the treatment of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). The trial is being conducted at the University of Texas MD Anderson Cancer Center (MDACC) and is listed...

February 3, 2025 1 EN
 PRESS RELEASE
Free
SLRX Salarius Pharma...

Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Me...

Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement Decoy’s proprietary IMP3ACT™ peptide conjugate drug design and manufacturing platform leverages machine learning (ML) and artificial intelligence (AI) tools Decoy is leveraging non-dilutive funding and equivalents from federal governments, corporations and The Bill & Melinda Gates Foundation totaling approximately $7 million Combined company expects to accelerate clinical development of novel peptide conjugate therapeutics for the treatment of respiratory viruses and cancer HOUSTON and CAMBRIDGE, Mass., ...

January 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch